Economic evaluation of the introduction of the Prostate Health Index as a rule-out test to avoid unnecessary biopsies in men with prostate specific antigen levels of 4-10 in Hong Kong
Open Access
- 16 April 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (4) , e0215279
Abstract
A recent study showed that the Prostate Health Index may avoid unnecessary biopsies in men with prostate specific antigen 4-10ng/ml and normal digital rectal examination in the diagnosis of prostate cancer in Hong Kong. This study aimed to conduct an economic evaluation of the impact of adopting this commercially-available test in the Hong Kong public health service to determine whether further research is justified. A cost-consequence analysis was undertaken comparing the current diagnostic pathway with a proposed diagnostic pathway using the Prostate Health Index. Data for the model was taken from a prospective cohort study recruited at a single-institution and micro-costing studies. Using a cut off PHI score of 35 to avoid biopsy would cost HK$3,000 and save HK$7,988 per patient in biopsy costs and HK$511 from a reduction in biopsy-related adverse events. The net cost impact of the change was estimated to be HK$5,500 under base case assumptions. At the base case sensitivity and specificity for all grades of cancer (61.3% and 77.5% respectively) all grade cancer could be missed in 4.22% of the population and high grade cancer in 0.53%. The introduction of the prostate health index into the diagnostic pathway for prostate cancer in Hong Kong has the potential to reduce biopsies, biopsy costs and biopsy-related adverse events. Policy makers should consider the clinical and economic impact of this proposal.Keywords
Funding Information
- Health and Medical Research Fund (Reference No.: 02160047)
This publication has 18 references indexed in Scilit:
- A multi-centre evaluation of the role of Prostate Health Index (PHI) in regions with different prevalences of prostate cancer: A different reference range is needed for European and AsianEuropean Urology Supplements, 2018
- Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volumeInternational Urology and Nephrology, 2016
- The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health IndexValue in Health, 2016
- Prostate cancer in Asia: A collaborative reportAsian Journal of Urology, 2014
- The Prostate Health Index: a new test for the detection of prostate cancerTherapeutic Advances in Urology, 2013
- Cost‐effectiveness of Prostate Health Index for prostate cancer detectionBJU International, 2011
- Budget impact analysis of a new prostate cancer risk index for prostate cancer detectionProstate Cancer and Prostatic Diseases, 2011
- [-2]Proenzyme Prostate Specific Antigen is More Accurate Than Total and Free Prostate Specific Antigen in Differentiating Prostate Cancer From Benign Disease in a Prospective Prostate Cancer Screening StudyJournal of Urology, 2010
- False-negative Prostate Needle Biopsies: Frequency, Histopathologic Features, and Follow-upAmerican Journal of Surgical Pathology, 2010
- PSA-based Screening for Prostate Cancer: How Does It Compare with Other Cancer Screening Tests?European Urology, 2008